Related Experiment Video

Updated: Dec 10, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer

Mathieu Chevallier1, Petros Tsantoulis1, Alfredo Addeo1

  • 1Oncology Department, Geneva University Hospital, Geneva, Switzerland.

Cancer Genomics & Proteomics
|August 30, 2020
PubMed
Abstract

Insights

Concurrent resistance mutations in non-EGFR genes significantly impact survival for non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Non-resistance mutations did not affect outcomes, underscoring the importance of comprehensive molecular profiling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) patients with EGFR mutations benefit from TKIs.
  • Treatment resistance remains a challenge, potentially due to co-occurring mutations.
  • Understanding these co-mutations is crucial for optimizing NSCLC therapy.

Purpose of the Study:

  • To investigate the impact of concurrent mutations outside the EGFR gene on survival outcomes.
  • To analyze how different types of co-mutations (resistance vs. non-resistance) affect patients treated with TKIs for EGFR-mutated NSCLC.

Main Methods:

  • Retrospective cohort analysis of advanced NSCLC patients treated with TKIs.
  • Evaluation of clinical data, EGFR mutational status, and co-occurring genetic alterations.
  • Assessment of overall survival (OS) and progression-free survival (PFS).

Main Results:

  • 52% of patients had no concurrent mutations, 36% had non-resistance co-mutations, and 12% had resistance co-mutations.
  • Patients with concurrent resistance mutations showed significantly shorter median OS (7.7 months) compared to those without (18.1 months).
  • PIK3CA, KRAS, and PTEN were identified as genes with mutations potentially associated with resistance.

Conclusions:

  • Concurrent resistance mutations in genes other than EGFR negatively influence survival in EGFR-mutated NSCLC patients on TKIs.
  • Non-resistance co-mutations did not significantly alter survival outcomes.
  • Comprehensive molecular profiling and careful interpretation of findings are essential for personalized NSCLC treatment.
Keywords:
EGFRNSCLCco-mutationsconcurrent mutationsosimertinibresistance

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
562
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.3K